| Drug Name |
Maraviroc |
| Drug ID |
BADD_D01352 |
| Description |
Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. |
| Indications and Usage |
For treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. |
| Marketing Status |
Prescription |
| ATC Code |
J05AX09 |
| DrugBank ID |
DB04835
|
| KEGG ID |
D06670
|
| MeSH ID |
D000077592
|
| PubChem ID |
3002977
|
| TTD Drug ID |
D0NR6S
|
| NDC Product Code |
69037-0062; 49702-223; 50923-0414; 12828-0091; 49702-260; 49702-235; 69037-0061; 31722-579; 49702-233; 31722-580; 68554-0040; 49702-237; 76072-1019; 49702-224 |
| Synonyms |
Maraviroc | 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide | Selzentry | UK-427,857 | UK 427,857 | UK427,857 | UK-427857 | UK 427857 | UK427857 |
